HBI-002

DRUG3 trials

Sponsors

Hillhurst Biopharmaceuticals, Inc.

Conditions

Anemia, Sickle CellParkinson Disease

Phase 1

A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers

CompletedNCT03926819

Hillhurst Biopharmaceuticals, Inc.Anemia, Sickle Cell

Start: 2022-07-25End: 2023-04-26Updated: 2025-05-23

A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

RecruitingNCT06144749

Hillhurst Biopharmaceuticals, Inc.Anemia, Sickle Cell

Start: 2025-02-15End: 2026-06-30Target: 9Updated: 2026-01-08

Phase 2

Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

Not yet recruitingNCT07005180

Hillhurst Biopharmaceuticals, Inc.Parkinson Disease

Start: 2026-02-28End: 2027-03-31Target: 36Updated: 2026-01-08

Related Papers

Clinical safety of oral administration of hbi-002 carbon monoxide drug product in healthy subjects and individuals with sickle cell disease

Blood2025-11-03